Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation

Detalhes bibliográficos
Autor(a) principal: Brandão,Vanessa B. A.
Data de Publicação: 2014
Outros Autores: Faria,Luciana C., Bicalho,Danielle M., Pereira,Fernando H., Lima,Agnaldo S., Ferrari,Teresa C. A.
Tipo de documento: Artigo
Idioma: eng
Título da fonte: MedicalExpress (São Paulo. Online)
Texto Completo: http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300143
Resumo: OBJECTIVE: To investigate risk factors for the development of chronic kidney disease and death two years postliver transplantation. METHOD: Associations between clinical and laboratory parameters and the development of chronic kidney disease and survival two years post-liver transplant were analyzed in a cohort of 148 adult patients with hepatic cirrhosis consecutively submitted to liver transplantation in a referral Brazilian center. RESULTS: Median age at liver transplantation was 56 (range, 20-73) years, and 105 (70.9%) patients were males. The prevalence of chronic kidney disease at two years post-liver transplantation was: stage 1 or no chronic kidney disease, 27.5%; stage 2, 33.8%; stage 3, 34.6%; stages 4-5, 4.7%. Four variables were independently associated with the stage of chronic kidney disease two years after liver transplantation: (i) age (at liver transplantation), (ii) male gender, (iii) median tacrolimus levels in the first three months post-liver transplantation, and (iv) median of serum creatinine in the first six months post-liver transplantation. Two variables showed independent association with death in two years post-liver transplantation: (i) stay in Intensive Care Unit for three or more days after the liver transplantation surgery and (ii) median of serum creatinine levels in the first six months post-liver transplantation equal or higher than 1.3 mg/dL. CONCLUSIONS: Administration of the lowest effective dose of tacrolimus and adoption of strategies to spare renal function are important measures to reduce the risk of late chronic kidney disease and death post-liver transplantation especially in high risk patients.
id METC-1_f010e338e3d20c4f4e11c591cd4437e6
oai_identifier_str oai:scielo:S2358-04292014000300143
network_acronym_str METC-1
network_name_str MedicalExpress (São Paulo. Online)
repository_id_str
spelling Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantationChronic kidney diseaseKidney dysfunctionLiver transplantationTacrolimus OBJECTIVE: To investigate risk factors for the development of chronic kidney disease and death two years postliver transplantation. METHOD: Associations between clinical and laboratory parameters and the development of chronic kidney disease and survival two years post-liver transplant were analyzed in a cohort of 148 adult patients with hepatic cirrhosis consecutively submitted to liver transplantation in a referral Brazilian center. RESULTS: Median age at liver transplantation was 56 (range, 20-73) years, and 105 (70.9%) patients were males. The prevalence of chronic kidney disease at two years post-liver transplantation was: stage 1 or no chronic kidney disease, 27.5%; stage 2, 33.8%; stage 3, 34.6%; stages 4-5, 4.7%. Four variables were independently associated with the stage of chronic kidney disease two years after liver transplantation: (i) age (at liver transplantation), (ii) male gender, (iii) median tacrolimus levels in the first three months post-liver transplantation, and (iv) median of serum creatinine in the first six months post-liver transplantation. Two variables showed independent association with death in two years post-liver transplantation: (i) stay in Intensive Care Unit for three or more days after the liver transplantation surgery and (ii) median of serum creatinine levels in the first six months post-liver transplantation equal or higher than 1.3 mg/dL. CONCLUSIONS: Administration of the lowest effective dose of tacrolimus and adoption of strategies to spare renal function are important measures to reduce the risk of late chronic kidney disease and death post-liver transplantation especially in high risk patients.Mavera Edições Técnicas e Científicas Ltda2014-06-01info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersiontext/htmlhttp://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300143MedicalExpress v.1 n.3 2014reponame:MedicalExpress (São Paulo. Online)instname:Mavera Edições Científicas e Técnicas Ltda-MEinstacron:METC10.5935/MedicalExpress.2014.03.09info:eu-repo/semantics/openAccessBrandão,Vanessa B. A.Faria,Luciana C.Bicalho,Danielle M.Pereira,Fernando H.Lima,Agnaldo S.Ferrari,Teresa C. A.eng2016-06-06T00:00:00Zoai:scielo:S2358-04292014000300143Revistahttp://www.medicalexpress.net.brhttps://old.scielo.br/oai/scielo-oai.php||medicalexpress@me.net.br2358-04292318-8111opendoar:2016-06-06T00:00MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-MEfalse
dc.title.none.fl_str_mv Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
title Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
spellingShingle Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
Brandão,Vanessa B. A.
Chronic kidney disease
Kidney dysfunction
Liver transplantation
Tacrolimus
title_short Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
title_full Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
title_fullStr Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
title_full_unstemmed Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
title_sort Early serum tacrolimus levels predict long-term chronic kidney disease after liver transplantation
author Brandão,Vanessa B. A.
author_facet Brandão,Vanessa B. A.
Faria,Luciana C.
Bicalho,Danielle M.
Pereira,Fernando H.
Lima,Agnaldo S.
Ferrari,Teresa C. A.
author_role author
author2 Faria,Luciana C.
Bicalho,Danielle M.
Pereira,Fernando H.
Lima,Agnaldo S.
Ferrari,Teresa C. A.
author2_role author
author
author
author
author
dc.contributor.author.fl_str_mv Brandão,Vanessa B. A.
Faria,Luciana C.
Bicalho,Danielle M.
Pereira,Fernando H.
Lima,Agnaldo S.
Ferrari,Teresa C. A.
dc.subject.por.fl_str_mv Chronic kidney disease
Kidney dysfunction
Liver transplantation
Tacrolimus
topic Chronic kidney disease
Kidney dysfunction
Liver transplantation
Tacrolimus
description OBJECTIVE: To investigate risk factors for the development of chronic kidney disease and death two years postliver transplantation. METHOD: Associations between clinical and laboratory parameters and the development of chronic kidney disease and survival two years post-liver transplant were analyzed in a cohort of 148 adult patients with hepatic cirrhosis consecutively submitted to liver transplantation in a referral Brazilian center. RESULTS: Median age at liver transplantation was 56 (range, 20-73) years, and 105 (70.9%) patients were males. The prevalence of chronic kidney disease at two years post-liver transplantation was: stage 1 or no chronic kidney disease, 27.5%; stage 2, 33.8%; stage 3, 34.6%; stages 4-5, 4.7%. Four variables were independently associated with the stage of chronic kidney disease two years after liver transplantation: (i) age (at liver transplantation), (ii) male gender, (iii) median tacrolimus levels in the first three months post-liver transplantation, and (iv) median of serum creatinine in the first six months post-liver transplantation. Two variables showed independent association with death in two years post-liver transplantation: (i) stay in Intensive Care Unit for three or more days after the liver transplantation surgery and (ii) median of serum creatinine levels in the first six months post-liver transplantation equal or higher than 1.3 mg/dL. CONCLUSIONS: Administration of the lowest effective dose of tacrolimus and adoption of strategies to spare renal function are important measures to reduce the risk of late chronic kidney disease and death post-liver transplantation especially in high risk patients.
publishDate 2014
dc.date.none.fl_str_mv 2014-06-01
dc.type.driver.fl_str_mv info:eu-repo/semantics/article
dc.type.status.fl_str_mv info:eu-repo/semantics/publishedVersion
format article
status_str publishedVersion
dc.identifier.uri.fl_str_mv http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300143
url http://old.scielo.br/scielo.php?script=sci_arttext&pid=S2358-04292014000300143
dc.language.iso.fl_str_mv eng
language eng
dc.relation.none.fl_str_mv 10.5935/MedicalExpress.2014.03.09
dc.rights.driver.fl_str_mv info:eu-repo/semantics/openAccess
eu_rights_str_mv openAccess
dc.format.none.fl_str_mv text/html
dc.publisher.none.fl_str_mv Mavera Edições Técnicas e Científicas Ltda
publisher.none.fl_str_mv Mavera Edições Técnicas e Científicas Ltda
dc.source.none.fl_str_mv MedicalExpress v.1 n.3 2014
reponame:MedicalExpress (São Paulo. Online)
instname:Mavera Edições Científicas e Técnicas Ltda-ME
instacron:METC
instname_str Mavera Edições Científicas e Técnicas Ltda-ME
instacron_str METC
institution METC
reponame_str MedicalExpress (São Paulo. Online)
collection MedicalExpress (São Paulo. Online)
repository.name.fl_str_mv MedicalExpress (São Paulo. Online) - Mavera Edições Científicas e Técnicas Ltda-ME
repository.mail.fl_str_mv ||medicalexpress@me.net.br
_version_ 1754734596573888512